[On the determination of azapropazone from plasma by direct quantitative thin-layer chromatography (author's transl)].
For the purpose of investigating drug interactions, a new selective method for determination of 5-dimethylamino-9-methyl-2-propyl-1H-pyrazolo[1,2-a] [1,2,4]benzotriazine-1,3(2H)-dione-dihydrate (azapropazone, Prolixan 300) was developed. The method is based upon the direct quantitation of the drug by thin-layer chromatography using remission measurement. The method is well suited for routine analysis of numerous samples, because of its simplicity and rapidity. The standar deviation of the method is about +/-4% at therapeutic plasma concentrations.
D000284:Administration, Oral; D000328:Adult; D001032:Apazone / Q000008:administration & dosage / Q000097:blood*; D002855:Chromatography, Thin Layer / Q000379:methods*; D003124:Colorimetry / Q000379:methods; D006801:Humans; D013997:Time Factors; D014227:Triazines / Q000097:blood*
D014227:Triazines; D001032:Apazone
Uber die Bestimmung von Azapropazon aus Plasma durch direkte quantitative Dünnschichtchromatographie.